The Potential of Rebastinib in Platinum-Resistant Ovarian Cancer Treatment
Erika Hamilton, MD, discusses the mechanism of action of rebastinib, which is currently being explored in combination with weekly paclitaxel 1b/2 study of patients with platinum-resistant ovarian cancer.
Erika Hamilton, MD, director of the Breast Cancer and Gynecologic Cancer Research Program and principal investigator at Sarah Cannon Research Institute, discusses the mechanism of action of rebastinib, which is currently being explored in combination with weekly paclitaxel 1b/2 study of patients with platinum-resistant ovarian cancer.
Rebastinib is a switch control inhibitor that targets the TIE2 pathway. A hypothesis about its ability to enhance the effects of weekly paclitaxel lead to its use in this study.
Transcription:
0:08 | This was a study of weekly paclitaxel in combination with rebastinib. Rebastinib is an oral drug that inhibits TIE2. This is in the angiogenesis pathway, so you can think of it like a VEGF [pathway], except it hits a few additional targets as well. So [it is] a proven strategy for ovarian cancer targeting with both chemotherapy and an antiangiogenesis drug.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
